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Abstract: The specific targeting of protein-protein interactions by 
phosphoserine-containing small molecules has been scarce due to 
the dephosphorylation of phosphoserine and its charged nature at 
physiological pH, which hinders its uptake into cells. To address these 
issues, we herein report the synthesis of phosphoserine aryloxy 
triester phosphoramidates as phosphoserine prodrugs, which are 
enzymatically metabolized to release phosphoserine. This 
phosphoserine masking approach was applied to a phosphoserine-
containing inhibitor of 14-3-3 dimerization, and the generated 
prodrugs exhibited improved pharmacological activity. Collectively, 
this provided a proof of concept of the masking of phosphoserine with 
biocleavable aryloxy triester phosphoramidate masking groups as a 
viable intracellular delivery system for phosphoserine-containing 
molecules. Ultimately, this will facilitate the discovery of 
phosphoserine-containing small molecule therapeutics. 
Protein phosphorylation at serine residues is a fundamental 
phenomenon that is used by cells to affect the function, 
localization and degradation of proteins.[1] In some cases, 
phosphorylated serine residues mediate protein-protein 
interactions via the docking of the phosphoserine residue 
into a positively charged pocket within the partner protein. An 
example of this is the serine phosphorylation of the adaptor 
protein 14-3-3, which facilitates its homodimerization.[2] 
Attempts at inhibiting these phosphoserine-mediated 
protein-protein interactions with small molecules have mostly 
led, by design, to small molecules that lack phosphoserine. 
The move to discard phosphoserine groups from these 
molecules was driven by the fact that phosphoserine carries 
two negative charges at physiological pH, which limit its 
(passive) cellular uptake.[3] Additionally, phosphoserine is 
also subject to dephosphorylation by alkaline phosphatases, 
a process that yields serine-containing derivatives that do not 
often retain potent pharmacological activity compared to their 
parent phosphoserine-containing molecules. Although the 
masking of the phosphate group of phosphoserine was 
previously investigated, the study was limited to a 
phosphoserine mimetic (difluoromethylenephosphoserine) 
and not the natural phosphoserine moiety.[4] With this in mind 
and in order to improve the drug-like properties of 
phosphoserine-containing small molecules, we explored the 
application of the aryloxy triester phosphoramidate 
technology to phosphoserine. This technology has been 
widely used to mask the 5’-O-monophosphate groups of 
nucleotides, and has so far led to two FDA-approved drugs; 
sofosbuvir and tenefovir alafenamide.[5]  
As a proof of concept, we initially synthesized phosphoserine with 
the aryloxy triester phosphoramidate masking groups (Figure 1a). 
For this, the N- and C-terminals of phosphoserine had to be 
protected[6] first to allow for the selective addition of the aryloxy 
triester phosphoramidate moiety to the side chain hydroxyl group. 
The synthesis was initiated by the chlorination of tert-butanol (1) 
by copper(I) chloride with the peptide coupling reagent N,N'-
dicyclohexylcarbodiimide (DCC).[6] The generated compound, 2, 
was then reacted with the commercially available N-Boc L-serine, 
3, in DCM to yield the N- and C-protected L-serine 4.[6] This latter 
compound was subsequently reacted with phenyl L-alanine 
methyl ester phosphorochloridate (7), which had been 
synthesized according to reported procedures[7] by reacting L-
alanine methyl ester hydrochloride (6) with the commercially 
available phenyl dichlorophosphate (5) in DCM and in the 
presence of triethylamine (NEt3). This reaction yielded the desired 
phosphoserine aryloxy triester phosphoramidate, compound 8, as 
a white solid in a good yield (62%). 
With the phosphoserine aryloxy triester phosphoramidate in hand, 
we first studied whether the aryl and amino acid ester groups that 
mask the phosphate group of phosphoserine could be 
metabolized in vitro to release the unmasked phosphoserine 
species. It is now well established that the metabolism of the 
aryloxy triester phosphoramidate moieties is  initiated by the 
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metabolite A (Figure 1b).[5a, 8] The formed carboxylate group then 
performs a nucleophilic attack onto the phosphate group leading 
to the release of the aryl group and the formation of a highly 
unstable five-membered anhydride ring (metabolite B, Figure 1b). 
This is subsequently opened up by a water molecule to generate 
the phosphoramidate metabolite C (Figure 1b). Finally, the 
phosphoramidase-type enzyme Hint-1[9] cleaves the P-N bond of 
metabolite C to release the unmasked monophosphate group. 
With this in mind, we incubated compound 8 at 37 °C with 
commercially available recombinant carboxypeptidase Y and 
monitored the sample by 31P-NMR (Figure 1c).  
As shown in Figure 1c, at t = 0 min, the 31P-NMR of 
compound 8 shows a sharp two singlets (dp = 3.1 and 3.2 
ppm), which correspond to the two diastereoisomers (R and 
S) of the phosphoserine aryloxy triester phosphoramidate. 
This is typical of the aryloxy triester phosphoramidates as 
they have a chiral phosphorous and most current synthetic 
routes yield these compounds as a mixture of two 
diastereoisomers.[5a, 7b, 10] After 5 minutes incubation with 
recombinant carboxypeptidase Y, two new peaks appeared; 
one appeared briefly at dp = 4.1 ppm while another peak at 
dp = 6.4 ppm also appeared and remained throughout the 
rest of the experiment. This is typical for aryloxy triester 
phosphoramidates as previous studies using 
carboxypeptidase Y showed a similar pattern with the peak 
at  dp = 4.1 ppm corresponding to metabolite A whilst that at 
dp = 6.4 ppm corresponding to metabolite C (Figure 1b).[10-
11] Notably, after 30 minutes incubation, only the 31P-NMR 
peak at dp = 3.2 ppm remained from the two 31P-NMR peaks 
of the parent compound 8. This indicated that one of the 
diastereoisomers of phosphoserine phosphoramidate, which 
has a 31P-NMR that corresponds to dp = 3.1 ppm, is a better 
substrate for the enzyme and thus was processed quicker. 
From 30 minutes onward, only two 31P-NMR peaks 
persisted; dp = 3.2 and 6.4 ppm. After 18 h, the peak at dp = 
6.4 ppm became the major peak with only one of the peaks 
from the original phosphoserine phosphoramidate two 
singlets remained. Mass spectrometry analysis of the 
products generated from this in vitro enzymatic assay after 
18 h confirmed the breakdown of the phosphate masking 
groups and the release of metabolite C (Supporting Figure 
S1). As in this in vitro assay, there was no phosphoramidase-
type enzyme, metabolite C was not further processed to 
release the fully unmasked phosphoserine species. To 
predict whether metabolite C would be a good substrate for 
Hint-1, we performed in silico docking of the metabolite into 
the crystal structure of the human Hint-1 co-crystallized with 
AMP (PDB 1KPF) as previously reported.[10] The results 
showed that metabolite C sits in the Hint-1 active site and the 
phosphate group of phosphoserine  forms key interactions 
with catalytic residues of Hint-1 (serine107, histidine112 and 
histidine114) suggesting that it could be a good substrate for 
this enzyme (Supporting Figure S2).[9b] These docking 
results are in line with previous docking studies for the same 
enzyme that predicted and verified whether the P-N bond of 
the docked substrates  could be cleaved off by Hint-1.[9b] 
Together, these results indicate that phosphoserine aryloxy 
triester phosphoramidates are metabolized in a similar 
fashion to the nucleoside monophosphate aryloxy triester 
phosphoramidates.  
In order to establish the applicability of the aryloxy triester 
phosphoramidate approach in improving the 
pharmacological activity of phosphoserine-containing 
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Fig. 1. Synthesis and in vitro esterase-mediated metabolism of phosphoserine aryloxy triester phosphoramidates. A. Synthesis of a phosphoserine aryloxy triester 
phosphoramidates (8). B. Mechanism of aryloxy triester phosphoramidates metabolism. C. 31P-NMR in vitro enzymatic assay of the breakdown of the 
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dimerization inhibitor 13 (Figure 2), which showed 
promising, but not potent activity in cells.[12] This compound 
is an ideal candidate for the application of the aryloxy triester 
phosphoramidate technology as it contains a phosphoserine 
motif that is essential for its pharmacological activity.[12]  
The synthesis of the aryloxy triester phosphoramidates of 
compound 13 commenced by the regioselective benzylation 
of the side chain hydroxyl group of N-Boc-L-serine (3), which 
proceeded with 70% yield (Figure 2a). The carboxylic acid 
of the product, 9, was then conjugated to the amine group of 
tyramine to form a peptide bond using the peptide coupling 
reagent PyBOP in THF in the presence of NEt3. This was 
then followed by sequential deprotection of the amine group 
and the side chain hydroxyl moiety using trifluoroacetic acid 
in DCM and hydrogenation, respectively. This resultant 
compound 11 was reacted with compound 18, which had 
been generated[13] in two steps from the commercially 
available 4-azidobenzoic acid (Figure 2b), to generate 
compound 12.  
For the synthesis of the reported 14-3-3 dimerisation 
inhibitor, 13, compound 12 was reacted with N,N,N’,N’-
tetramethylphosphorodiamidic chloride in MeCN in the 
presence of the Grignard reagent tertbutyl magnesium 
chloride (tBuMgCl). The generated phosphorodiamidate 
derivative was then converted to the desired monophosphate 
species, 13, by treatment with HCl in dioxane. We also 
synthesized the derivative of compound 13 where the 
phosphate group is fully masked by diethyl groups, 
compound 14, to be used as a negative control in the 
biological assays. The synthesis was achieved by reacting 
compound 12 with diethyl chlorophosphate in the presence 
of tBuMgCl in MeCN to flourish the desired compound 14 in 
30% yield. For the synthesis of the aryloxy triester 
phosphoramidates of the 14-3-3 dimerization inhibitor, 13, 
the synthesis was accomplished by coupling compound 12 
to the appropriate phosphorochloridate (7, 20a or 20b, 
Figure 2c) in the presence of tBuMgCl in MeCN to give the 
desired aryloxy triester phosphoramidates (15a-c), as a 
mixture of two diastereoisomers, in low yields (~ 30%). 
Notably, the phosphorochloridates 7, 20a-b were 
synthesised as shown in Figure 2c and reported 
previously.[7]  
In order to determine the efficacy of the synthesized aryloxy 
triester phosphoramidate prodrugs to inhibit 14-3-3 
dimerization and cell proliferation, we treated the lung cancer 
cell line, A549, with the 14-3-3 dimerization inhibitor, 13, its 
diethyl phosphate derivative, 14, and the aryloxy triester 
phosphoramidates 15a-c as well as compound 12 at the 
indicated concentrations (12.5, 25, 50 and 100 µM) for 48 
and 72 h (Figure 3). Cell viability was then determined using 
standard MTT assays. The results showed that, as expected, 
the unphosphorylated compound 12, its phosphorylated 
derivative 13 and the diethyl phosphate compound 14, did 
not show any significant effect on cell viability. 
Encouragingly, the aryloxy triester phosphoramidates 15a-c, 
apart from 15a, did show significant dose-dependent 
reduction of A549 cell viability (Figure 3). This is because 
these aryloxy triester phosphoramidates are neutral at 
physiological pH, unlike the parent compound 13, and thus 
they are more readily taken up by cells via passive diffusion. 
The fact that among this series of aryloxy triester 
phosphoramidates, the isopropyl and benzyl ester 
phosphoramidates (15b and 15c, respectively) showed 
significant biological activity and the methyl ester 
phosphoramidate, 15a, did not demonstrate profound 
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13: R1 = R2 = OH.
14: R1 = R2 = Et.
15a: R3 = Me (29%).
15b: R3 = iPr (27%).
15c: R3 = Bn (29%).






















7: R4 = Me (84%).
20a: R4 = iPr (85%).
20b: R4 = Bn (83%).
L-alanine amino acid 
ester hydrochloride
1) For compound 13:
a. N,N,N',N'-Tetramethylphosphorodiamidic 
chloride, tBuMgCl, MeCN, 24 h, 25%.
b. HCl, dioxane, 24 h, 99%.
2) For compound 14: 
Diethyl chlorophosphate, tBuMgCl, 
MeCN, 24 h, 30%.
7, 20a-c, tBuMgCl, MeCN, 24 h.
Fig. 2. A. Synthesis of the phosphoserine-containing 14-3-3 dimerization inhibitor (13), diethyl phosphate (14) and its aryloxy triester phosphoramidates (15a-c). 
The serine motif is shown in red while its phosphate and masked phosphate groups are shown in blue. B. Synthesis of the intermediate 2-((4-
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activity relationship of aryloxytriester phosphoramidates of 
5’-O-nucleoside monophosphates.[5a, 7b]  
In summary, masking the phosphate group of phosphoserine 
with an aryl motif and an amino acid ester serves as a useful 
approach for the intracellular delivery of phosphoserine. 
Indeed, this work showed using a combination of in vitro 
enzymatic and in silico docking studies that these 
phosphoserine aryloxy triester phosphoramidates are 
metabolized to release the unmasked phosphoserine moiety. 
The application of this approach to a 14-3-3 phosphoserine-
containing molecule significantly improved its 
pharmacological efficacy in cancer cells. Together, this 
validates this approach of phosphoserine masking with 
biocleavable motifs, and  this will in the future facilitate the 
discovery of phosphoserine-containing molecules as 
powerful tool compounds and potential therapeutics.  
Experimental Section 
Experimental details are found in the Supporting Information. 
Keywords: Phosphoserine • Phosphoramidate • Prodrug • 14-3-
3 • Cancer 
 [1] a) T. Pawson, J. D. Scott, Trends Biochem. Sci. 2005, 30(6), 286-290; b) 
T. Hunter, Cell 1995, 80(2), 225-236; c) P. Cohen, Trends Biochem. Sci. 
1992, 17(10), 408-413. 
[2] M. B. Yaffe, K. Rittinger, S. Volinia, P. R. Caron, A. Aitken, H. Leffers, S. J. 
Gamblin, S. J. Smerdon, L. C. Cantley, Cell 1997, 91(7), 961-971. 
[3] L. Xie, S. Y. Lee, J. N. Andersen, S. Waters, K. Shen, X. L. Guo, N. P. 
Moller, J. M. Olefsky, D. S. Lawrence, Z. Y. Zhang, Biochemistry 2003, 
42(44), 12792-12804. 
[4] A. Arrendale, K. Kim, J. Y. Choi, W. Li, R. L. Geahlen, R. F. Borch, Chem. 
Biol. 2012, 19(6), 764-771. 
[5] a) Y. Mehellou, H. S. Rattan, J. Balzarini, J. Med. Chem.  2018, 61(6), 2211-
2226; b) Y. Mehellou, ChemMedChem 2016, 11(11), 1114-1116. 
[6] S. Koch, D. Schollmeyer, H. Lowe, H. Kunz, Chemistry  2013, 19(22), 7020-
7041. 
[7] a) M. S. Davey, R. Malde, R. C. Mykura, A. T. Baker, T. E. Taher, C. S. Le 
Duff, B. E. Willcox, Y. Mehellou, J. Med. Chem. 2017; b) L. Osgerby, Y. C. 
Lai, P. J. Thornton, J. Amalfitano, C. S. Le Duff, I. Jabeen, H. Kadri, A. 
Miccoli, J. H. R. Tucker, M. M. K. Muqit, Y. Mehellou, J. Med. Chem.  2017, 
60(8), 3518-3524. 
[8] a) G. Birkus, R. Wang, X. Liu, N. Kutty, H. MacArthur, T. Cihlar, C. Gibbs, 
S. Swaminathan, W. Lee, M. McDermott, Antimicrob. Agents Chemother. 
2007, 51(2), 543-550; b) J. Balzarini, A. Karlsson, S. Aquaro, C. F. Perno, 
D. Cahard, L. Naesens, E. De Clercq, C. McGuigan, Proc. Nat. Acad. Sci. 
USA 1996, 93(14), 7295-7299. 
[9] a) J. Cheng, X. Zhou, T. F. Chou, B. Ghosh, B. Liu, C. R. Wagner, Bioorg. 
Med. Chem. Lett. 2009, 19(22), 6379-6381; b) E. Murakami, T. Tolstykh, H. 
Bao, C. Niu, H. M. Steuer, D. Bao, W. Chang, C. Espiritu, S. Bansal, A. M. 
Lam, M. J. Otto, M. J. Sofia, P. A. Furman, J. Biol. Chem. 2010, 285(45), 
34337-34347. 
[10] Y. Mehellou, R. Valente, H. Mottram, E. Walsby, K. I. Mills, J. Balzarini, C. 
McGuigan, Bioorg. Med. Chem. 2010, 18(7), 2439-2446. 
[11] M. Slusarczyk, M. H. Lopez, J. Balzarini, M. Mason, W. G. Jiang, S. 
Blagden, E. Thompson, E. Ghazaly, C. McGuigan, J. Med. Chem. 2014, 
57(4), 1531-1542. 
[12] H. Wu, J. Ge, S. Q. Yao, Angew. Chem. 2010, 49(37), 6528-6532. 
[13] H. Garrido-Hernandez, K. D. Moon, R. L. Geahlen, R. F. Borch, J. Med. 
Chem.  2006, 49(11), 3368-3376.  
Fig. 3. Cell viability of the unmasked phosphoserine compound (12), phosphoserine-containing 14-3-3 dimerization inhibitor (13), its diethyl phosphate derivatives 
(14) and the aryloxy triester phosphoramidates (15a-c). Cell viability was determined by standard MTT assay. The compounds were incubated with A549 lung 
cancer cell line for 48 h (white bar) and 72 h (grey bar) at the indicated concentrations. The percentage of cell viability was calculated and presented as normalized 
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The development of phosphoserine-containing therapeutics has been limited by their poor drug-like properties. To address this, we 
applied the aryloxy triester phosphoramidate prodrug technology to phosphoserine and a phosphoserine-containing 14-3-3- 
dimerization inhibitor. These prodrugs exhibited improved biological activity highlighting the promise of this prodrug technology in the 
discovery of phosphoserine-containing therapeutic.  
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